These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
    Author: Reshetnikov V, Arkhypov A, Julakanti PR, Mokhir A.
    Journal: Dalton Trans; 2018 May 15; 47(19):6679-6682. PubMed ID: 29708261.
    Abstract:
    We prepared a Pt(iv)-prodrug, which under cancer specific conditions (elevated concentration of reactive oxygen species, ROS) releases a DNA-binding drug oxaliplatin as well as ROS-amplifying drugs p-quinone methide and N-alkylferrocenium. Due to the concerted action of these components, an excellent anticancer effect was achieved: IC50 = 0.4 ± 0.1 μM for human ovarian carcinoma A2780 cells. Importantly, the prodrug was found to be 45-fold less toxic to normal cells (HDFa).
    [Abstract] [Full Text] [Related] [New Search]